Der RAS-RAF-MEK-ERK-Signalweg

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Univ.-Prof. Dr. Robert Loewe

Abteilung für Allgemeine Dermatologie und Dermatoonkologie sowie Skin and Endothelium Research Division (SERD), Universitätsklinik für Dermatologie, Medizinische Universität Wien


Referenzen:

– Baines AT et al., Inhibition of Ras for cancer treatment: the search continues. Future Medicinal Chemistry 2011 3:1787–1808

– Baker NM, Der CJ, Cancer: Drug for an ‚undruggable‘ protein. Nature 2013; 497:577–578

– BosJL, ras Oncogenes in Human Cancer: A Review. Cancer Research 1989; 49:4682–4689

– Davies H et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417:949–954

– Engelman JA et al., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351–1356

– Flaherty et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine 2010; 363:809–819

– Flaherty KT et al., Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine 2012; 367:107–114

– Flaherty KT et al., Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine 2012; 367:1694–1703

– Hatzivassiliou G et al., ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors. Molecular Cancer Therapeutics 2012; 11:1143–1154

– McCubrey JA et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research 2007; 1773:1263–1284

– Nazarian R et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973–977

– Oberholzer PA et al., RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology 2012; 30:316–321

– Prior IA et al., A comprehensive survey of Ras mutations in cancer. Cancer Research 2012; 72:2457–2467

– Roberts PJ, Der CJ, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291–3310

– Santarpia L et al., Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012; 16:103–119

– Thakur MD, Stuart DD, Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors. Clinical Cancer Research 2014; 20:1074–1080

– Yoon S, Seger R, The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24:21–44

– Zhao Y, Adjei AA, The clinical development of MEK inhibitors. Nat Rev Clin Oncol 2014; 11:385–400

– Zimmermann G et al., Small molecule inhibition of the KRAS-PDE[dgr] interaction impairs oncogenic KRAS signalling. Nature 2013; 497:638–642


SO 05|2014

Herausgeber: Univ.-Prof. Dr. Christoph Zielinski, Univ.-Prof. Dr. Markus Raderer
Publikationsdatum: 2014-12-31